GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: IAMA-6 is a small molecule inhibitor of the basolateral Na-K-Cl symporter NKCC1 (SLC12A2). The chemical structure was disclosed during the 'First Time disclosures' session at the ACS Spring 2025 meeting in San Diego and this was matched to ARN23746/compound 1 in [1]. IAMA-6 is intended as an orally bioavailable agent that targets NKCC1-associated neuronal hyperexcitability as a mechanism to restore neuronal excitability as a treatment for neurological disorders, including autism and epilepsies in paediatric patients.
|
|
No information available. |
Summary of Clinical Use ![]() |
IAMA-6 is a therapeutic lead that has been progressed to clinical trial. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT06300398 | IAMA-6 Oral Dose Study in Healthy Adults | Phase 1 Interventional | Iama Therapeutics S.r.l. |